Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MNPR with free AI briefings, catalyst countdowns, and dilution alerts.

MNPR · Monopar Therapeutics

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$129.4M Cash on Hand
82.4mo Cash Runway
Follow MNPR by email Get an email when MNPR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MNPR, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Clonidine HCl Mucoadhesive Buccal Tablet Chemoradiotherapy-Induced Severe Oral Mucositis Phase 2/3 · NCT04648020 Terminated
Camsirubicin Advanced Soft-tissue Sarcoma Phase 1 · NCT05043649 Terminated
MNPR-101-DFO*-89Zr Solid Tumor, Adult Phase 1 · NCT06337084 Active not recruiting
MNPR-101-PCTA-177Lu Solid Tumor, Adult Phase 1 · NCT06617169 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MNPR holds $129.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.7M/quarter from operations, an estimated runway of 82.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MNPR files for a raise →

👥 Who Owns MNPR

Insiders 9.4% Other 5%+ holders 7.7% Institutions (140 holders) 82.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 1,119,413 16.52% 2026-09-30
RA Capital Management, L.P. Institution (13G, 5%+) 667,632 9.85% 2025-12-31
AstraZeneca PLC 5%+ holder (13G) 522,667 7.71% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 338,133 4.99% 2026-09-30
Tactic Pharma LLC
10% owner
Insider 272,026 4.01% 2025-09-24
Chandler Robinson
Chief Executive Officer, Director · +336,934 options
Insider 166,942 2.46% 2026-10-20
Diane Hendricks
10% owner
Insider 93,750 1.38% 2025-12-16
Andrew Cittadine
Chief Operating Officer · +135,351 options
Insider 58,054 0.86% 2026-09-30
Christopher M Starr
Director · +11,324 options
Insider 15,053 0.22% 2026-10-01
Kim R Tsuchimoto
Director · +13,139 options
Insider 11,486 0.17% 2026-11-02
Arthur J Klausner
Director · +2,924 options
Insider 8,762 0.13% 2025-12-18
Raymond Anderson
Director · +8,868 options
Insider 5,373 0.08% 2026-11-02

Share count 6,776,773 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MNPR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MNPR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.